Holen Sie sich die Stockscreener-App
50.24
2.01%
0.99
Handel nachbörslich:
46.50
-3.74
-7.44%
Schlusskurs vom Vortag:
$49.25
Offen:
$49.05
24-Stunden-Volumen:
1.08M
Relative Volume:
0.63
Marktkapitalisierung:
$6.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-10.92
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
+1.43%
1M Leistung:
+18.97%
6M Leistung:
+54.39%
1J Leistung:
-45.21%
1-Tages-Spanne:
$48.79
$50.27
1-Wochen-Bereich:
$47.02
$50.27
52-Wochen-Spanne:
$27.66
$94.76
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
50.24 | 6.45B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
EBIT per share of Vaxcyte, Inc. – DUS:5VA - TradingView
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound - Yahoo Finance
How Vaxcyte Inc. stock reacts to Fed rate cutsWeekly Trade Report & Free Technical Pattern Based Buy Signals - newser.com
Is Vaxcyte Inc. stock vulnerable to regulatory risksEarnings Growth Report & Risk Managed Investment Entry Signals - newser.com
Will Vaxcyte Inc. stock continue upward momentumQuarterly Trade Review & Accurate Trade Setup Notifications - newser.com
Is Vaxcyte Inc. (5VA) stock a top hedge fund pickJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners By Investing.com - Investing.com South Africa
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners - Investing.com Australia
PCVX: 31-Valent vaccine nears phase III, targeting major market growth and expanded global demand - TradingView
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
What analyst consensus says on Vaxcyte Inc. stockTrade Entry Report & High Conviction Trade Alerts - newser.com
(PCVX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Can momentum traders help lift Vaxcyte Inc.July 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Is Vaxcyte Inc. stock poised for growthEarnings Trend Report & Daily Technical Forecast Reports - newser.com
Will Vaxcyte Inc. benefit from macro trendsPortfolio Risk Summary & Safe Capital Allocation Plans - newser.com
Vaxcyte, Inc.Common Stock (NQ: PCVX - Markets Financial Content
Vaxcyte Inc Stock Analysis and ForecastStock Split Announcements & High Profit Portfolio Growth - earlytimes.in
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vaxcyte (BIT:1PCVX) Price Target Decreased by 15.42% to 72.37 - Nasdaq
Is Vaxcyte’s (PCVX) Aggressive R&D Spend Still Justified Amid Widening Losses? - simplywall.st
Should you wait for a breakout in Vaxcyte Inc.July 2025 Review & High Conviction Investment Ideas - newser.com
Quantitative breakdown of Vaxcyte Inc. recent move2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Has Vaxcyte Inc. found a price floorBond Market & Smart Investment Allocation Insights - newser.com
Can Vaxcyte Inc. (5VA) stock attract analyst upgrades2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Using data tools to time your Vaxcyte Inc. exitChart Signals & Daily Market Momentum Tracking - newser.com
Vaxcyte, Inc. (5VA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Will Vaxcyte Inc. stock benefit from commodity prices2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Vaxcyte’s Stock Juggle: Opportunity or Risk? - StocksToTrade
What moving averages say about Vaxcyte Inc.Market Rally & Reliable Breakout Forecasts - newser.com
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):